By Tiffany Hu ( May 17, 2021, 3:50 PM EDT) -- The U.S. Supreme Court on Monday opted to leave alone a ruling that Amgen Inc.'s patents for its blockbuster autoimmune drug Enbrel weren't invalid for double-patenting, effectively blocking Sandoz Inc. from selling a biosimilar version of the drug until 2029....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.